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Abstract
Background: Acute lung injury (ALI) induces a coagulation/fibrinolysis imbalance and leads to fibrin
deposition. The protein C pathway is an important regulator of the coagulation system and reduces the
inflammatory response. The aim of the study was to examine the effects of recombinant human activated
protein C (rhAPC) in the early phase of Pseudomonas aeruginosa (Pa)-induced lung injury.
Methods: The study was conducted in vivo on a rat model of Pa-induced ALI. Continuous intravenous
(IV) rhAPC was administrated simultaneously with intratracheal (IT) Pa. We instilled into the airspaces a
5% bovine albumin solution with 1 µ(Ci of 125 I-albumin and injected IV 1 µ(Ci of 111In-albumin to measure
lung liquid clearance (LLC) and endothelial injury. Cytokines levels (TNFα and IL-6) and thrombin-
antithrombin (TAT) complexes were measured in blood and bronchoalveolar lavage fluid (BALF) at 4
hours. Four groups were compared: control (CTR), pneumonia (PNP) receiving IT Pa (0.5 ml/kg of 1 × 109
cfu), APC: IV rhAPC (300 µg/kg/h), A-PNP: IT Pa /IV rhAPC.
Results: Alveolar-capillary permeability was increased in the PNP versus the CTR group (0.28 ± 0.08 vs.
0.03 ± 0.01, p < 0.05). IV rhAPC in Pa-induced ALI led to further injury (0.47 ± 0.17 vs. 0.28 ± 0.08, p =
0.2). The LLC was significantly decreased in the A-PNP group compared to PNP group (9.1 ± (4.3% vs.
33.4 ± 2.6%, p < 0.05). The lung wet to dry weight ratio was significantly increased in the PNP group (4.62
± 0.31) compared to the CTR group (3.87 ± 0.22, p < 0.05). IV rhAPC administration tends to increase
this parameter in Pa-induced ALI (5.80 ± 0.66, p = 0.07). These findings were associated with a loss of
inflammatory response compartmentalization measured by TNFα and IL-6 systemic levels. TAT
complexes in BALF were increased in the A-PNP group (23.17 ± 2.89 ng/ml) compared to the CTR group
(0.92 ± 0.17 ng/ml, p < 0.05) and the PNP group (11.06 ± 2.76 ng/ml, p < 0.05).
Conclusion:  rhAPC reduces LLC following Pa-induced ALI and may influence pulmonary edema
formation. The early massive fibrin formation is probably beneficial in ALI limiting both the extent of injury
and permeability disorders.
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Background
Pseudomonas aeruginosa (Pa) is one of the most frequent
pathogens involved in nosocomial pneumonia [1]. This
Gram-negative bacillus is associated with a mortality rate
reaching 70% in some studies and an attributable mortal-
ity approaching 40% [2]. Instillation of this pathogen into
the air spaces increases the protein permeability of the
lung barrier to induce both interstitial and alveolar edema
[3]. Active ion transport is the primary mechanism driving
alveolar liquid clearance in the normal lung [4]. The
maintenance of active ion transport is critical for the reso-
lution of alveolar edema [5,6]. Moreover, improvement of
fluid reabsorption from the air spaces in the Pa-induced
lung injury in an experimental rat model of pneumonia is
associated with a decrease in mortality [7].
Despite the improvement of ventilatory strategies, Acute
Respiratory Distress Syndrome (ARDS), the most severe
form of acute lung injury (ALI), is associated with a mor-
tality estimated to 35 % [8]. ALI is characterized by a
sequence of pathological events which can be subdivided
into three phases: the acute or exsudative phase, a sub-
acute or proliferative phase, and finally a chronic or
fibrotic phase [9,10]. During the exsudative phase, exten-
sive epithelial and endothelial damages result in intra-
alveolar deposition of fibrin [11], which is the hallmark of
a shift in the coagulation/fibrinolysis balance.
Several studies focused on this pro-coagulative imbalance
during ALI: an increase in bronchoalveolar pro-coagulant
activity associated with a depressed bronchoalveolar fibri-
nolysis activity has been found in animal models as well
as humans [12-14]. In fact, depressed bronchoalveolar
urokinase plasminogen activator activity was found in
clinical ARDS [15], this decreased bronchoalveolar fibri-
nolysis activity was associated with an increased fibrinol-
ysis inhibition related to plasminogen activator inhibitor
(PAI-1) [14]. As a consequence to this procoagulant activ-
ity associated with decreased fibrinolysis activity, a
fibrotic evolution could be triggered [14,16] and influ-
ence patient's outcome [17]. From these data, the modu-
lation of the lung coagulation/fibrinolysis balance
appears to be a potential therapeutic approach in ALI and
ARDS [18].
Protein C is a natural anticoagulant with an important
role in coagulation homeostasis through proteolytic
cleavage and inactivation of factors Va and VIIIa [19]. Acti-
vated protein C has also been shown to restore a pro-fibri-
nolytic activity by inhibiting PAI-1, and to reduce the
inflammatory response through a limitation of thrombin
generation and a modulation of nuclear factor-(B translo-
cation [19]. In vivo, activated protein C reduces pulmo-
nary injury in a model of LPS-induced ALI [20]. Moreover,
a therapeutic effect was observed in septic baboons [21]
and in humans severe sepsis with a major decrease in mor-
tality [22].
The aim of our study was therefore to evaluate, in a rat
model, the effects of recombinant human activated pro-
tein C (rhAPC) in the early phase of Pseudomonas aerugi-
nosa-induced lung injury. We evaluated the effect of
rhAPC co-administration in a rat model of Pa-induced
lung injury on lung permeability and lung fluid move-
ment. Finally, alveolar and systemic cytokines were meas-
ured along with coagulation parameters to complete these
functional studies.
Methods
1. Animals
Specific pathogen-free Sprague Dawley rats (n = 50) (280–
320 g, Charles River Laboratoires France, St Germain/
l'Arbresle, France) were housed in the Lille University Ani-
mal Care Facility and allowed food and water ad lib. All
experiments were performed with approval of the Lille
Institutional Animal Care and Use Committee.
2. In vivo study
2.1. Surgical preparation
Sprague-Dawley male rats were anesthetized with pento-
barbital (Sanofi, Libourne, France). An endotracheal tube
(PE-220) was inserted through a tracheotomy. The rats
were ventilated with a constant volume pump (Harvard
Apparatus, South Natick, MA), with an inspired O2 frac-
tion of 1.0, a respiratory rate of 60/min and a positive end
expiratory pressure of 2 cmH2O. A catheter (PE-50) was
inserted into the left carotid artery to monitor systemic
arterial pressure and obtain blood samples. Low molecu-
lar weight heparin was injected into the catheter (100 UI/
kg). Pancuronium bromide (0.3 mg/kg/h iv) was admin-
istered to achieve neuromuscular blockade.
2.2. General protocol
For all experiments, the following general protocol was
used. After the surgical preparation, heart rate and blood
pressure were allowed to stabilize. The rat was then placed
in left lateral decubitus to facilitate liquid deposition into
the left lung.
To calculate the flux of plasma protein into the lung inter-
stitium, a vascular tracer, 1 µCi of 111In-labeled human
serum albumin (HSA), was injected into the bloodstream
[7,23]. 111In-HSA was prepared in our institution accord-
ing to a standardized technique [24]. To calculate the alve-
olar liquid clearance, 3 ml/kg of a 5% bovine albumin
solution containing 1 µCi of 125 I-albumin were instilled
30 min later into the left lung over a 2-min period, using
a 1-ml syringe and polypropylene tube (0.5 mm internal
diameter) [7,23].Respiratory Research 2006, 7:41 http://respiratory-research.com/content/7/1/41
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One hour after the beginning of albumin instillation, the
abdomen was opened, and the rat was exsanguinated.
Urine was sampled for radioactivity levels. The lungs were
removed through a sternotomy, and fluid from the distal
airspaces was obtained by passing a propylene tube (0.5
mm internal diameter) into a wedged position in the left
lower lobe. The total protein concentration and the radio-
activity of the liquid sampled were measured. Right and
left lungs were homogenized separately for water to dry
weight ratio measurements and radioactivity levels.
2.3. Preparation of albumin instillate
The test solution used for albumin instillation was pre-
pared as follows: briefly, a 5% bovine albumin solution
was prepared using Ringer lactate and adjusted with NaCl
to be isoosmolar with the rat circulating plasma [7,23].
We added 1 µCi of 125 I-labeled human serum albumin
(125 I-HSA; CIS biointernational, Gif sur Yvette, France) to
the 5% albumin solution. Anhydrous Evan's blue dye (0.5
mg) was added to confirm the location of the instillate at
the end of the study. A sample of the instilled solution was
saved for total protein measurement, radioactivity counts,
and water to dry weight ratio measurements so that the
dry weight of the protein solution could be substracted
from the final lung water calculation.
2.4. Measurements
Hemodynamics, pulmonary gas exchange, and protein concentration
Systemic arterial pressure and airway pressures were meas-
ured continuously (Acknowledge Software v3.7.1, Biopac
Systems, Santa Barbara, CA, USA). Arterial blood gases
were measured at one-hour intervals (ABL 520, Radiome-
ter, Copenhagen). The arterial PO2 was used to quantify
the oxygenation deficit [25]. Samples from instilled pro-
tein solution, final distal airspace fluid, initial and final
blood were collected to measure total protein concentra-
tion with an automated analyzer (Hitachi 917, Japan).
Lung barrier function study
Permeability of the alveolar-capillary barrier was assessed
with the measure of the albumin flux. 111In-albumin
counts in the final airspace sample were compared to
plasma 111In-albumin counts averaged over the course of
the experiment; permeability to the tracer was expressed
as a ratio of airspace to plasma counts (Asp/Plasma). As
previously shown [3], this ratio provides a good index of
equilibration of the vascular protein tracer into the alveo-
lar compartment.
Accumulation of the vascular protein tracer into the
extravascular space of the lung was calculated by deter-
mining the total extravascular count of 111In-albumin in
the lung divided by the average counts in the plasma over
the study period and was expressed as total plasma equiv-
alents (TPE) in microliters [26].
Lung liquid clearance
The extravascular lung water (EVLW) was measured by the
gravimetric method [7,25]. For each animal, the nonin-
stilled lung was used to calculate EVLW and estimate lung
liquid clearance (LLC) [25,25].
Alveolar fluid movement
Changes of native bovine albumin concentration over the
study period (1 h) were used to measure alveolar fluid
movement. The term "alveolar" does not imply that all
fluid reabsorption occurred at the alveolar level, since
some reabsorption may have occurred across distal bron-
chial epithelium.
The alveolar liquid clearance (ALC) was measured by the
ratio of the final unlabeled alveolar protein concentra-
tion, compared to the initial instilled alveolar protein
concentration (ALCprot) [23,27]. The concentrations of
alveolar 125 I-albumin were also used to estimate alveolar
liquid clearance (ALC125) [27].
Measuring alveolar liquid clearance with this methodol-
ogy relies mainly on the calculation of the alveolar vol-
ume, which may, in the context of ALI, be falsely
evaluated. We therefore had to validate this method in
this particular situation. Five percent albumin solution
with 125 I-albumin was sampled one minute after albumin
instillation into the airspaces of the rats with ALI. This
early sampling allowed to the measurement of the change
in the concentration of labeled and unlabeled protein
related dilution by non-labeled protein-rich alveolar
edema fluid [27]. We performed the experiments in three
animals and observed no change in labeled and unlabeled
protein (data not shown).
3. P. aeruginosa-induced lung injury
Pseudomonas aeruginosa (PaO1 strain) was incubated in
125 ml of tryptic soy broth at 37°C in a rotating shaking
water bath for 8 hours. The culture was then washed twice
with phosphate-buffered saline, and resuspended in
phosphate-buffered saline. The resulting bacterial suspen-
sion was at 1 × 109 CFU/ml. ALI was produced according
to the method described by Pennington and Ehrie [28].
Under short ether anesthesia, a small midline incision was
made on the neck ventral surface after swabbing it with
ethanol. The trachea was exposed by blunt dissection.
Using a 28-gauge needle, 0.5 ml/kg of bacterial suspen-
sion was instilled into the trachea, followed by injection
of 0.5 ml of air. The animals were studied in vivo 4 hours
after instillation of bacteria.
4. Recombinant human activated protein C
Recombinant human activated protein C (rhAPC) was
generously provided by Lilly SAS (Saint-Cloud, France).
Animals were anesthetized with 60 mg/kg of ketamineRespiratory Research 2006, 7:41 http://respiratory-research.com/content/7/1/41
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associated with 1 mg/kg of chlorpromazine chlorhydrate
intra-muscularly. A Silastic catheter (Dow corning Corpo-
ration, Milland, MI) was inserted into the superior vena
cava via the right external jugular vein. The catheter was
tunneled subcutaneously to the interscapular region.
Resuspended rhAPC was then continuously administered
at 300 (µg/kg/h during 4 hours intravenously. This dosage
regimen was chosen according to manufacturer's recom-
mendation, taking into account the species differences in
rhAPC activity.
5. Bronchoalveolar lavage (BAL)
Lungs from each experimental group were lavaged with a
total of 20 ml in 5-ml aliquots of PBS with 3 mM EDTA.
The returned fluid was pooled and centrifuged (200 g for
10 min), and the cellular pellet was washed two times in
PBS. A cell count was performed directly with a hemocy-
tometer, and the total number of cells was calculated. Cel-
lular monolayers were prepared with a cytocentrifuge and
stained with Wright-Giemsa stain. Cellular morphotype
differential was obtained by counting 200 cells/sample
and expressing each type of cell as a percentage of the total
number counted.
6. Cytokines assays
Levels of tumor necrosis factor α (TNFα and interleukin 6
(IL-6) were determined after treatment by use of commer-
cially immunoassay kits (ELISA) specific for rat cytokines
(respectively, Quantikine Murine rat TNFα and Quantik-
ine Murine rat IL-6, R&D Systems, Abingdon OX, UK).
The reading was performed with a microplate reader
Digiscan (Spectracount Packard Instrument Company;
Meriden CT USA). Levels were measured in the serum and
in BAL fluids of animals from each group 4 hours post-
instillation of bacteria.
7. Coagulation
The following parameters were measured 4 hours post-
instillation of bacteria in blood samples obtained through
direct aortic catheterization of anesthetized rats from each
group: leukocyte and platelet counts, prothrombin time,
fibrinogen and thrombin-antithrombin (TAT) complex
concentrations. Measurements of TAT complexes were
used as markers of thrombin formation [33]. TAT com-
plexes were also measured in BAL fluids. Platelet and leu-
kocyte counts were obtained on EDTA-treated
uncoagulated blood. For coagulation assays, blood (four
parts) was collected into sodium citrate 3.8% (one part).
Platelet depleted plasma was separated by centrifugation
(15°C at 2500 g for 15 min). Prothrombin time, fibrino-
gen concentration (Clauss' method) were measured
immediately by standard procedures. These two parame-
ters were measured to detect the occurrence of an overt
intravascular coagulation leading to a consumptive coag-
ulopathy and fibrinogen depletion. Other assays were per-
formed on frozen plasma or BAL fluid stored at -80°C.
TAT complexes were measured on citrated samples by an
enzyme-linked immunosorbent assay method (Enzyg-
nost® TAT, Behringwerke AG, Marburg, Germany).
8. Experimental groups
Animals were randomized to one of four groups with a
sample size of 5 animals per group in each series of exper-
iments (in vivo permeability, alveolar liquid clearance,
BAL, cytokines, histology and coagulation studies):
Experimental protocol over time Figure 1
Experimental protocol over time. The animals are followed during a four hours period. After the instillation of Pseudomonas 
aeruginosa (Pa) or isotonic saline, rhAPC (APC) or saline is injected continuously during the next four hours of the experiment. 
After anesthesia and tracheotomy, 111I-labeled albumin is injected intravenously (IV), 150 minutes after the beginning of the 
experiment. Sixty minutes prior to sacrifice, 125 I-labeled albumin is instilled intratracheally (IT). The animals are then sacrificed 
for each of the functionnal studies described in the method section.
135 min 15 min 30 min 60 min
Instillation Pa/Saline
APC/Saline IV
Anesthesia
Tracheotomy
111I-Alb IV
125I-Alb IT SacrificeRespiratory Research 2006, 7:41 http://respiratory-research.com/content/7/1/41
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- Control group (CTR): saline (0.5 ml/kg intratracheal
injection)
- Pa (PNP): Pa (0.5 ml/kg of 1 × 109 cfu intratracheal inoc-
ulum)
- rhAPC group (APC): saline (0.5 ml/kg intratracheal
injection), treated (300 µg/kg/h IV rhAPC)
- rhAPC/Pa group (A-PNP): Pa (0.5 ml/kg of 1 × 109 cfu
intratracheal inoculum), treated (300 µg/kg/h IV rhAPC).
For each protocol the timing was similar as represented on
Figure 1
9. Statistical analysis
Results are presented as mean ± SEM. Data were analyzed
using the Kruskall-Wallis test and the Mann Whitney test
where appropriate. P values less than 0.05 were regarded
as statistically significant. StatView 4.57 (Abacus Concept,
Berkeley, CA, USA) software was used. A Bonfferoni cor-
rection was used for multiple analysis.
Results
rhAPC administration worsens oxygenation impairment in 
P.aeruginosa lung injury
Systemic arterial and airway pressures showed no signifi-
cant differences between the different groups in any series
of experiments (Table 1). PaO2/FiO2 ratio showed no sta-
tistically significant differences between CTR, APC and
PNP groups. However, rhAPC administration signifi-
cantly impaired oxygenation compared to CTR and PNP
groups (Table 1).
rhAPC does not further increase alveolar-capillary protein 
permeability in early P. aeruginosa-induced lung injury
Endothelial permeability, evaluated by the leakage of the
vascular marker into the alveoli (Asp/Plasma ratio), was
significantly increased in the PNP group versus control
animals (0.28 ± 0.08 vs. 0.03 ± 0.01, p < 0.05). Concom-
itant administration of rhAPC further increased this leak-
age compared to the PNP group, but the difference did not
reach a statistical significance (0.47 ± 0.17 vs. 0.28 ± 0.08,
p = 0.2) (Figure 2). Consistent with this finding, bacterial
instillation led to a significant increase in total plasma
equivalents (TPE) compared to the CTR group (0.22 ±
0.03 vs. 0.07 ± 0.03, p < 0.05). rhAPC administration
increased TPE in the A-PNP group compared to the PNP
group, but this increase remained below a statistical sig-
nificance (0.37 ± 0.15 vs. 0.22 ± 0.03, p = 0.33) (Figure 2).
rhAPC administration induces an increase in extra-
vascular lung water and a decrease in LLC
The lung wet to dry weight (W/D) ratio was significantly
increased in the PNP group (4.62 ± 0.31) compared with
the CTR group (3.87 ± 0.22, p < 0.05). Concomitant
administration of rhAPC tended to increase the W/D ratio
following Pa-induced ALI (5.80 ± 0.66, p = 0.07) (Table
2).
Pa-induced ALI was associated with a significant increase
in LLC versus control animals. In contrast, rhAPC co-
administration decreased significantly LLC compared
with PNP animals (Table 2).
Alveolar fluid clearance calculated from native proteins as
well as labeled proteins showed increased values in the
PNP group versus the CTR group (respectively, 47.9 ± 4.7
% vs. 27.4 ± 2.8 %, p < 0.05 and 34.6 ± 4.5 % vs. 24.2 ±
2.5 %, p < 0.05). Administration of rhAPC did not influ-
ence this parameter (Figure 3).
rhAPC increases lung inflammatory cell recruitment in Pa-
induced lung injury
The number of inflammatory cells recovered from the BAL
fluid was significantly increased in the PNP group com-
pared with the CTR group (9.2 ± 3.5 × 106 cells/ml vs. 1.7
± 0.7 × 106 cells/ml, p < 0.05). This value was further
increased in the A-PNP group (38.1 ± 4.4 × 106 cells/ml, p
< 0.05).
More than 90% of the cells were alveolar macrophages in
control and APC animals. For PNP animals, neutrophils
represented 85.5 ± 4.5 % of the cells. rhAPC administra-
tion induced a significant increase of neutrophils com-
pared to the PNP group (95.7 ± 1.3 %, p < 0.05).
Table 1: In-vivo systolic arterial pressure (SAP), airway pressure (AWP) and PaO2/FiO2 ratio after a 30 minutes stabilization period.
Group SAP (mm Hg) AWP (cm H2O) PaO2/FiO2
CTR 127 ± 5 4.3 ± 0.4 420 ± 37
APC 118 ± 16 4.8 ± 0.6 483 ± 47
PNP 123 ± 20 4.1 ± 0.3 386 ± 33
A-PNP 104 ± 12 4.1 ± 0.6 215 ± 26† ‡
Data are means ± SEM. † p < 0.05 vs. CTR, ‡ p < 0.05 vs. PNP.Respiratory Research 2006, 7:41 http://respiratory-research.com/content/7/1/41
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rhAPC administration induces a loss of 
compartmentalization of the inflammatory response
In the BAL fluid, TNFα was non detectable in CTR and
APC groups. These cytokines were significantly increased
in both the PNP and the A-PNP groups (p < 0.05) (Table
3). Interestingly, in the serum, TNFα was non detectable,
even after Pa instillation. rhAPC co-administration led to
a significant increase in TNFα systemic levels (p < 0.05). A
comparable pattern was observed with IL-6, major levels
were obtained in the A-PNP group (p < 0.05), significantly
higher than in the PNP group (Table 3).
The levels of alveolar coagulation biomarkers are majored 
by rhAPC administration in P.aeruginosa-induced lung 
injury
A significant decrease in white blood cell count was
observed in Pa inoculated groups compared with the con-
trol group (p < 0.05). A decreased platelet count was
observed in the APC group (Table 4). Concerning plasma
fibrinogen levels, a significant increase was observed in
the PNP group compared with control animals (p < 0.05),
whereas a significant decrease was observed in the APC
and the A-PNP groups compared with controls (p < 0.05)
(Table 4). Plasma TAT complexes were comparable
between all the groups.
In the alveoli, analysis of the BAL fluid showed a statisti-
cally significant increase in TAT complexes in the PNP
group versus CTR group (11.06 ± 2.76 vs. 0.92 ± 0.18 ng/
ml, p < 0.05). Moreover, TAT complexes in the BAL fluid
were significantly increased in the A-PNP group, com-
pared with the PNP group (23.17 ± 2.89 vs 11.06 ± 2.76
ng/ml, p < 0.05) (Figure 4).
Discussion
In our study, Pa-induced lung injury led to an increase in
alveolar-capillary barrier permeability and rhAPC admin-
istration tended to increase extra-vascular lung water in
the A-PNP group. Analysis of lung fluid movement
showed an increase in alveolar lung clearance in pneu-
monic animals. If the epithelial transport was relatively
preserved in our model, endothelial function alterations
were observed with a decrease of lung liquid clearance
after rhAPC administration in pneumonic animals. Con-
sistent with these findings, rhAPC treated animals had a
loss of lung cytokines compartmentalization as assessed
with TNFα and IL-6 systemic levels. The analysis of coag-
ulation parameters showed a major increase of TAT com-
plexes in the BAL fluid associated with the increased
permeability.
In the first part of our study, we showed an increase in the
alveolar-capillary barrier permeability after instillation of
the bacteria. Our results are consistent with previous find-
ings, we showed a leak of the vascular tracer into the alve-
oli (Asp/Plasma ratio) [7,27] associated with an increase
in the total plasma equivalents (TPE) [26].
Concomitant administration of rhAPC in Pa-induced
lung injury group further tended to increase extra-vascular
lung water in the A-PNP group. Murakami et al. showed
that APC pretreatment could reduce permeability disor-
ders and histological damages in a model of LPS-induced
pulmonary vascular injury [29]. These effects were related
to APC ability to inhibit pulmonary accumulation of leu-
kocytes. Our results are not consistent with these findings;
however, the type of injury induced in our model differs
from that of Murakami et al. First, in our model, the lung
injury was induced by a living bacteria instillation and not
only by a component of this bacteria; toxic substances
Table 2: Lung wet to dry weight (W/D) ratio and lung liquid 
clearance (LLC) for each group.
Group W/D ratio LLC (%)
CTR 3.87 ± 0.22 23.5 ± 2.9
APC 4.16 ± 0.34 20.3 ± 2.2
PNP 4.62 ± 0.31* 33.4 ± 2.6†
A-PNP 5.80 ± 0.66† 9.1 ± 4.3† ‡
Data are means ± SEM; * p < 0.05 versus CTR, † p < 0.05 vs. CTR, ‡ p 
< 0.05 vs. PNP.
In-vivo alveolar-capillary protein permeability Figure 2
In-vivo alveolar-capillary protein permeability. Endothelial 
permeability, evaluated by determining leakage of the vascu-
lar marker (111In labeled albumin) into the alveoli as assessed 
by the aspirate radioactivity ratio (Asp/Plasma) (white bars), 
was significantly increased in PNP group versus control ani-
mals (0.28 ± 0.08 vs. 0.03 ± 0.01, p < 0.05). Concomitant 
rhAPC administration further increased this leakage com-
pared to PNP animals. The accumulation of the vascular pro-
tein tracer into the extravascular space of the lung (TPE) 
(black bars) was increased in the PNP group versus CTR. 
Concomitant rhAPC administration increased TPE compared 
to PNP animals. Data are means ± SEM. * p < 0.05 vs. CTR.
0
0,2
0,4
0,6
0,8
CTR APC PNP A-PNP
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(such as exotoxins) released by living P. aeruginosa could
explain the severity of the injury observed in our study.
Second, in the study of Murakami et al., the injury only
involved the endothelial side of the alveolar-capillary bar-
rier, when our model involves both sides [3]. Finally, in
our model, rhAPC administration was concomitant with
the Pa-induced lung injury; animals were pre-treated in
the study of Murakami et al.
An important and unexpected finding of this study was
that rhAPC reduced LLC in the A-PNP group. LLC, i.e. the
portion of the instillate which left not only the alveoli but
also the lung, was increased by the bacterial insult in the
PNP group. Concomitant rhAPC administration was
responsible for a significant alteration of this parameter.
Pulmonary edema resorption involves two main path-
ways: vascular and lymphatic [30]. The alveolar-capillary
barrier permeability was altered in both the A-PNP and
the PNP groups. The lung W/D weight ratio is the result of
the combination of ALC and LLC. In the PNP group, the
balance between alveolar liquid clearance and lung liquid
clearance could limit the increase in the lung W/D weight
ratio and therefore preserve gas exchange. In the A-PNP
group, the alteration of the endothelial barrier was proba-
bly responsible for the decrease in the lung liquid clear-
ance, as a consequence, lung W/D weight ratio increased
and gas exchange was altered. In this hypothesis, the wors-
ening of the oxygenation was not related to alveolar flood-
ing but to mismatched of V/Q. Our findings are consistent
with previous results of others indicating that alveolar epi-
thelium is more resistant than the lung endothelium to
acute lung injury [31-33]. We have also previously shown
in another model that this discrepancy between ALC and
LLC could be related to the endothelial barrier [34]. Here,
the increase in endothelial permeability in the A-PNP
group seems to overwhelm alveolar transport and as a
consequence be responsible for alveolar flooding.
We found a preservation of alveolar liquid clearance
(ALC) assessed by native and labeled albumin concentra-
tion variations. Four hours after bacterial instillation, ALC
was significantly increased compared to the control
group. We observed an increase from 27% to 48%, con-
sistent with previously published studies which showed
an increase from 30% to 45% in a comparable model
[27]. In these studies, the increase in ALC was related to a
TNFα-dependent mechanism [27] since it was completely
prevented by anti-TNFα antibody pretreatment and repro-
duced by TNFα instillation alone. In our study, we found
a high BAL fluid TNFα level in Pa-induced lung injury
groups, which can explain, at least partially, ALC increase.
A large number of studies has demonstrated the relation-
ship between systemic inflammation and the coagulation
system [35]. With inflammation, many cytokines are pro-
duced, among them TNF has been shown to inactivates
natural inhibitors of coagulation and attenuates fibrinol-
ysis, and IL-6 to activate coagulation [36]. We observed a
major increase in BAL fluid pro-inflammatory cytokines
levels in the PNP group compared to control animals,
In-vivo alveolar liquid clearance (ALC) Figure 3
In-vivo alveolar liquid clearance (ALC). ALC was calculated 
from the changes in concentration, expressed in percentages, 
of both labeled and unlabeled protein recovered in the aspi-
rate. ALC calculated from native protein (ALC prot) (white 
bars), showed increased values in the PNP and the A-PNP 
groups versus the CTR group (p < 0.05). Analysis of the 
results obtained from labeled proteins (ALC 125) (black bars) 
showed comparable values; both of the values in the PNP and 
A-PNP groups differed statistically from the CTR group (p < 
0.05). Data are means ± SEM. * p < 0.05 vs. CTR.
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Table 3: TNFα, and IL-6 levels in blood serum and BAL fluid for each group.
Group TNFα (pg/ml) IL-6 (pg/ml)
Blood serum BAL fluid Blood serum BAL fluid
CTR n.d. n.d. 171.6 ± 17.7 83.9 ± 2.1
APC n.d. n.d. 142.9 ± 16.9† 90.4 ± 14.5
PNP n.d. 957.2 ± 337.2†° 225.4 ± 57.0† 2706.0 ± 1720.1†°
A-PNP 19.3 ± 14.1†° ‡ 1697.0 ± 180.8†° ‡ 470.7 ± 111.5†° ‡ 4452.4 ± 1283.4†°
n.d.: non detectable.
Data are means ± SEM.† p < 0.05 vs. CTR, °p < 0.05 vs.APC, ‡ p < 0.05 vs. PNP.Respiratory Research 2006, 7:41 http://respiratory-research.com/content/7/1/41
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whereas these cytokines were non detectable or only
slightly increased in the blood. TNFα and IL-6 are mainly
released from macrophages and neutrophils both acti-
vated by different products from P.aeruginosa [37]. In the
PNP group, locally released cytokines remained within
the alveolar space [38], and blood serum cytokines levels
were lower than in the alveolar compartment. In the A-
PNP group, we observed a significant increase in both
blood serum TNFα and IL-6 levels compared to CTR and
PNP groups standing for a loss of compartmentalization
of the inflammatory response associated with systemic
mediators release [38,39].
rhAPC administration in Pa-induced lung injury led to a
4-fold increase in TAT complexes in the BAL fluid,
whereas blood serum values were not significantly differ-
ent between groups. Activated PC is a strong inhibitor of
factors Va and VIIIa and downregulates thrombin forma-
tion. In our model of experimental lung injury, the
increased TAT levels in the BAL fluid could represent an
indirect witness of the APC induced-increase in capillary-
alveolar permeability, leading to the migration and accu-
mulation of TAT complexes at the alveolar side. The lack
of a concomitant increase in plasma TAT levels is poorly
consistent with this mechanism. It is also well docu-
mented that alveolar epithelial cells are able to generate a
substantial amount of thrombin independently of any
intravascular coagulation activation. Alveolar macro-
phages are able to express tissue factor-dependent pro-
coagulant activity and synthesize factor V that accelerates
thrombin formation via the prothrombinase complex
[40]. The rat fetal distal lung epithelium has been used in
vitro to study epithelial thrombin formation and it has
been shown, by Chan et al, that lung epithelial cells pro-
mote thrombin generation via the expression of factor VII
dependent tissue factor activity [41]. On the other side,
these epithelial cells have also significant anticoagulant
properties. Bacterial LPS increases the expression of
thrombomodulin in alveolar macrophages and this effect
could enhance the activation of Protein C in the
thrombin-thrombomodulin complex. Epithelial cells
express on their cell surface glycoaminoglycans able to
bind to plasma Antithrombin (AT) and leading to the gen-
eration of TAT complexes in the alveolar fluid [41]. We
could document in a previous study that the levels of alve-
olar TAT complexes were greatly enhanced when recom-
binant human AT was infused intravenously in the same
Pa model, showing that a substantial amount of thrombin
had been generated in the alveolar fluid [42]. Therefore,
the possibility must be considered that the increase in TAT
alveolar levels observed in the present study after intrave-
nous APC infusion, might reflect the perturbation of the
complex pro and anti coagulation balance at the alveolar
level. Additionally, the effects of rhAPC on endothelial
permeability and epithelial cells are not uniform. Experi-
mental studies have shown that they may differ according
to the animal model, the dosage regimen, and the infu-
sion route. For instance, Zeng and al. have shown that
contrasting with a lack of effect at low dose, higher dose
(≥ 1 µg/mL) of rhAPC could induce an early endothelial
cell leakage [43]. These data suggest that interpretation of
the published in vitro and in vivo data of rhAPC and
endothelial permeability should take into consideration
the concentrations of rhAPC used or achieved. In the
present study we used the dosage of rhAPC recommended
by the manufacturer, taking into account that species dif-
ferences in APC activity require higher dose in the rat
model. Nevertheless we consider that our results support
Serum and bronchoalveolar lavage (BAL) fluid Thrombin- Antithrombin complexes (TAT) Figure 4
Serum and bronchoalveolar lavage (BAL) fluid Thrombin-
Antithrombin complexes (TAT). There was no significant 
variation between groups in blood serum TAT complexes 
(white bars). However, there was a significantly increase in 
BAL fluid TAT complexes (black bars) in the PNP group com-
pared to the CTR group. rhAPC administration in Pa-induced 
lung injury animals further increased BAL fluid TAT com-
plexes. Data are means ± SEM. * p < 0.05 vs. CTR and APC, 
° p < 0.05 vs. PNP.
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Table 4: Standard coagulation parameters for each group at 4 hours
Group WBC (109/l) Plt (109/l) PT (%) Fibrinogen (g/l)
CTR 6.69 ± 0.76 793 ± 59 52 ± 3 2.38 ± 0.13
APC 5.10 ± 0.91 580 ± 53† 43 ± 2 1.93 ± 0.11
PNP 3.63 ± 0.65† 850 ± 14° 52 ± 1 3.22 ± 0.36†°
A-PNP 2.77 ± 0.45† 778 ± 24° 46 ± 3 2.36 ± 0.11‡
WBC: white blood cells, Plt : Platelets, PT : Prothrombin time
Data are means ± SEM.† p < 0.05 vs. CTR, ° p < 0.05 vs. APC, ‡ p < 0.05 vs. PNP.Respiratory Research 2006, 7:41 http://respiratory-research.com/content/7/1/41
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the possibility that the infusion of rhAPC at the early stage
of bacterial pneumonia might disturb the complex coagu-
lation balance at the alveolar level and impede the initial
favorable effect of coagulation activation.
Indeed, during the earliest phase of acute lung injury, the
epithelial as well as the endothelial side of the alveolar-
capillary barrier are involved with a fibrin deposition on
both sides reflecting the shift in the alveolar coagulation/
fibrinolysis balance [10]. During the first 72 hours of
human ARDS, the procoagulant activity is maximal and
fibrinolytic activity is decreased; then, from the fourth to
the fifteenth day, fibrinolysis inhibition persists whereas
the procoagulant activity is moderately increased
[12,15,44,45]. In such a situation, the inhibition of fibrin
formation appears to be an attractive therapeutic
approach. However, the possibility of deleterious effects
of enhancing fibrinolysis or inhibiting intra-alveolar coag-
ulation in the early stages of ARDS has to be considered.
The early inhibition of thrombin formation by activated
PC at the endothelial side might impede the natural plug-
ging of the capillary alveolar leak induced by the bacterial
insult. This possibility is further supported by recent
results from our laboratory showing in the same rat model
that inhibition of thrombin formation by recombinant AT
also increases lung permeability and aggravates lung dam-
age [42]. Consistent with this hypothesis, rhAPC adminis-
tration in Pa-induced lung injury tends to increase extra-
vascular lung water with a loss of compartmentalization
of the inflammatory response. This finding underlines the
importance of early fibrin formation to limit the extent of
injury.
This study has several limitations before the extrapolation
of the results to clinical situations. Concerning the design
of the study, we used a model of acute lung injury in the
rat at the very early phase of the injury; patients are usually
seen at a later phase. We used recombinant human acti-
vated C protein in a rat model, the species difference can
explain the higher dose used in our study, however, the
dose was chosen according to the manufacturer's recom-
mendations at the time of the study. Finally, APC was
administered concomitantly, which is better than in pre-
treatment, but still far from the clinical use.
On the results obtained, we only have a limited number
of animals in each group and the measure of the alveolar
liquid clearance is always difficult with an increase of the
alveolar barrier permeability, however, we used the classi-
cal corrections to obtain a reliable parameter [27]. Finally,
the measure of the endothelial and epithelial permeability
relies on the study of a double flux of markers. The results
obtained reflect a combination of these two barriers per-
meabilities, a fine distinction could only be studied
through morphological data.
Conclusion
Our results show that administration of 300 µg/kg/h of
rhAPC in the early stage of Pa-induced lung injury tends
to increase lung edema formation with a loss of the
inflammatory response compartmentalization. These
effects could be related to the inhibition of thrombin for-
mation by rhAPC, suggesting a probable beneficial role of
early coagulation activation in ALI limiting both extents
of injury and permeability disorders. In a later stage of
ALI, the modulation of haemostasis by rhAPC could be of
value to restore the fibrinolytic capacities and limit the
intensity of inflammatory reaction [46].
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